|
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424. |
|
|
Patents, Royalties, Other Intellectual Property - US20180002762A1 |
|
|
Research Funding - Millennium (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - BTG; Monteris Medical |
Consulting or Advisory Role - Agios; Cancer Expert Now; Stemline Therapeutics |
Research Funding - ImmunoCellular Therapeutics; Incyte; Newlink Genetics; Novartis; Pfizer; Vascular Biogenics |
Other Relationship - ASCO; NCI |
|
|
Research Funding - Abbvie; Celgene; Tocagen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Barrow Neurological Institute |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Illumina (I) |
Research Funding - Elekta |
Patents, Royalties, Other Intellectual Property - signal transduction inhibitor in lymphoma (I) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Novocure |
Speakers' Bureau - Brainlab |
Research Funding - BMS Brazil; Merck |
Travel, Accommodations, Expenses - Abbvie; Brainlab; Novocure |
Other Relationship - UpToDate |
|
|
Stock and Other Ownership Interests - Cloud DX |
Consulting or Advisory Role - Abbvie; Ferring |
Speakers' Bureau - AstraZeneca |
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Oncoceutics |
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Karyopharm Therapeutics; Tocagen |
Research Funding - Novocure (Inst) |
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY |
(OPTIONAL) Uncompensated Relationships - Xcision Medical Systems |
|
|
No Relationships to Disclose |